From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

Last Updated: Friday, February 7, 2025

On January 17, 2025, the U.S. Food and Drug Administration approved datopotamab deruxtecan-dlnk for adult patients with unresectable or metastatic HR+ HER2- breast cancer. This approval came following efficacy results from the TROPION-Breast01 trial.

U.S. Food and Drug Administration
Advertisement
News & Literature Highlights
Advertisement
Advertisement